<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03021785</url>
  </required_header>
  <id_info>
    <org_study_id>Tmab-TK001-AMD-02</org_study_id>
    <nct_id>NCT03021785</nct_id>
  </id_info>
  <brief_title>A Study of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-related Macular Degeneration</brief_title>
  <official_title>A Multi-center, Open-label Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu T-Mab Biopharma Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu T-Mab Biopharma Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label study to evaluate the safety, pharmacokinetics,&#xD;
      immunogenicity, and preliminary efficacy of multiple intravitreal injection TK001 in patients&#xD;
      with AMD. It consists of core study (12 weeks) and extension study (40 weeks).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label study to evaluate the safety, pharmacokinetics,&#xD;
      immunogenicity, and preliminary efficacy of multiple intravitreal injection TK001 in patients&#xD;
      with AMD. It consists of core study (12 weeks) and extension study (40 weeks). In the core&#xD;
      study, patients will receive their assigned dose in a 50-μL solution administered as an&#xD;
      intravitreal injection every 4 weeks. In the extension study, they will be evaluated every 4&#xD;
      weeks and administrated PRN (pro re nata) with their assigned dose. The safety,&#xD;
      pharmacokinetics, immunogenicity, and preliminary efficacy of TK001 will be evaluated in the&#xD;
      core study, and will also be assessed in the extension study except pharmacokinetics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">October 18, 2017</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of ocular and systemic AEs (adverse events) and SAEs (serious adverse events) which are related to TK001 in the first 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Core Study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of ocular and systemic AEs (adverse events) and SAEs (serious adverse events) which are related to TK001 in the following 40 weeks</measure>
    <time_frame>40 weeks</time_frame>
    <description>Extension Study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Core Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Core Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum concentration (Tmax)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Core Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-Life (T½)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Core Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Best Corrected Visual Acuity at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Core Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the mean central retinal thickness at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Core Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the thickness of choroidal neovascularization at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Core Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the retinal thickness in the site of lesion which was the thickest at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Core Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in macular volume at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Core Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the area of choroidal neovascularization at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Core Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the area of leakage at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Core Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the total lesion size at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Core Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Positive for anti-TK001 antibody at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Core Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Best Corrected Visual Acuity at 52 weeks</measure>
    <time_frame>40 weeks</time_frame>
    <description>Extension Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the mean central retinal thickness at 52 weeks</measure>
    <time_frame>40 weeks</time_frame>
    <description>Extension Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the thickness of choroidal neovascularization at 52 weeks</measure>
    <time_frame>40 weeks</time_frame>
    <description>Extension Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the retinal thickness in the site of lesion which was the thickest at 52 weeks</measure>
    <time_frame>40 weeks</time_frame>
    <description>Extension Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in macular volume at 52 weeks</measure>
    <time_frame>40 weeks</time_frame>
    <description>Extension Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the area of choroidal neovascularization at 52 weeks</measure>
    <time_frame>40 weeks</time_frame>
    <description>Extension Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the area of leakage at 52 weeks</measure>
    <time_frame>40 weeks</time_frame>
    <description>Extension Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the total lesion size at 52 weeks</measure>
    <time_frame>40 weeks</time_frame>
    <description>Extension Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Positive for anti-TK001 antibody at 52 weeks</measure>
    <time_frame>40 weeks</time_frame>
    <description>Extension Study</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Neovascular Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>0.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the core study, patients will receive 0.5mg TK001 in a 50-μL solution administered as an intravitreal injection every 4 weeks. In the extension study, they will be evaluated every 4 weeks and administrated PRN (pro re nata) with their assigned dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the core study, patients will receive 1.0mg TK001 in a 50-μL solution administered as an intravitreal injection every 4 weeks. In the extension study, they will be evaluated every 4 weeks and administrated PRN (pro re nata) with their assigned dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the core study, patients will receive 1.5mg TK001 in a 50-μL solution administered as an intravitreal injection every 4 weeks. In the extension study, they will be evaluated every 4 weeks and administrated PRN (pro re nata) with their assigned dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TK001</intervention_name>
    <description>TK001 will be administered intravitreal injection.</description>
    <arm_group_label>0.5mg</arm_group_label>
    <arm_group_label>1.0mg</arm_group_label>
    <arm_group_label>1.5mg</arm_group_label>
    <other_name>anti-VEGF humanized monoclonal antibody injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Aged 45 - 80 years, male or female&#xD;
&#xD;
          -  Diagnosed with neovascular AMD and with active lesions&#xD;
&#xD;
          -  Best corrected VA for the studied eye≤20/40&#xD;
&#xD;
          -  With stable blood pressure, SBP&lt;140 mmHg and DBP&lt;90 mmHg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Limitation of eye diseases&#xD;
&#xD;
          -  With vitreous hemorrhage in studied eyes within two months preceding screening&#xD;
&#xD;
          -  With geographic atrophy, epiretinal membrane or intensive subfoveal hard exudates&#xD;
             which involved the foveal in studied eyes&#xD;
&#xD;
          -  With opacity of refractive media(e.g. apparent cataract) or contraction of pupils&#xD;
             which significantly interfered the visual test or assessment of anterior segment and&#xD;
             fundus in studied eyes&#xD;
&#xD;
          -  With pseudoexfoliation syndrome, intraocular hemorrhage resulting in decreased vision,&#xD;
             rhegmatogenous retinal detachment, macular hole or choroidal neovascularization (CNV)&#xD;
             for any reason except for AMD (such as fundus angioid streaks, ocular histoplasmosis,&#xD;
             pathologic myopia, trauma) in studied eyes&#xD;
&#xD;
          -  With apparent afferent pupillary defect(APD) in studied eyes&#xD;
&#xD;
          -  With Polypoidal Choroidal Vasculopathy (PCV) or Retinal Angiomatous Proliferation&#xD;
             (PAP) in studied eyes&#xD;
&#xD;
          -  With intraocular pressure higher than 25mmHg despite treatment&#xD;
&#xD;
          -  With VA for the fellow eyes&lt;20/200&#xD;
&#xD;
          -  With active inflammation in any eye, such as conjunctivitis, keratitis, scleritis,&#xD;
             blepharitis, endophthalmitis and uveitis The treatment of the eye&#xD;
&#xD;
          -  The studied eye received topical or grid photocoagulation more than twice or within 3&#xD;
             months preceding screening&#xD;
&#xD;
          -  The studied eye received the following intraocular surgery or laser treatment in&#xD;
             macular (such as macular translocation surgery, glaucoma filtering surgery,&#xD;
             transpupillary thermotherapy, macular photocoagulation, vitreous cutting surgery,&#xD;
             optic nerve dissection, optic nerve sheath membrane dissection). But patients who&#xD;
             received verteporfin photodynamic therapy, cataract surgery or YAG posterior capsular&#xD;
             dissection more than 3 months before screening will not be excluded.&#xD;
&#xD;
          -  Any eye received antiangiogenic drugs within 2 months preceding screening or patients&#xD;
             received systemic antiangiogenic drugs within 3 months preceding screening (such as&#xD;
             pegaptanib, aflibercept, ranibizumab, bevacizumab or conbercept)&#xD;
&#xD;
          -  Any eye received intraocular injection of corticosteroid drugs (such as triamcinolone&#xD;
             acetonide) within 3 months preceding screening, or periocular injection of&#xD;
             corticosteroid drugs within 1 month before screening Systemic diseases, treatment and&#xD;
             other conditions&#xD;
&#xD;
          -  With a history of allergy to sodium fluorescein and indocyanine green&#xD;
&#xD;
          -  PLT≤100×109/L, BUN or Cr&gt;1.5×ULN(Upper Limit of Normal), TT(thrombin time) or&#xD;
             PT(prothrombin time) &gt;1.0×ULN(Upper Limit of Normal), take anti-platelet aggregation&#xD;
             drugs or anticoagulants within 1 month before screening&#xD;
&#xD;
          -  With surgery within 1 month before screening, or with unhealed wound, ulcer, fracture&#xD;
             at present&#xD;
&#xD;
          -  Diabetic patients without the control of glucose or accompanied by diabetic&#xD;
             retinopathy&#xD;
&#xD;
          -  With a history of myocardial infarction within 6 months before screening&#xD;
&#xD;
          -  With activity disseminated intravascular coagulation and a tendency of significant&#xD;
             bleeding before screening&#xD;
&#xD;
          -  Systemic autoimmune disease&#xD;
&#xD;
          -  Any uncontrolled diseases (such as severe systemic diseases of mental, neurological,&#xD;
             cardiovascular, respiratory and malignancies)&#xD;
&#xD;
          -  Pregnant and lactating women or patients who cannot take contraceptive measures&#xD;
&#xD;
          -  Poor compliance&#xD;
&#xD;
          -  Patients who participated other clinical trials within 30 days before screening or was&#xD;
             taking other clinical trials at present&#xD;
&#xD;
          -  Patients who is considered unsuitable for enrollment by investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongwei Miao</last_name>
    <phone>+86(21)61160520</phone>
    <email>miaohongwei@sh-qingfeng.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese Academy of Medicine Sciences，Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>YouXin Chen</last_name>
      <phone>+86 138-0102-5971</phone>
      <email>chenyouxinpumch@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Province People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ZongMing Song</last_name>
      <phone>+86 188-0371-8289</phone>
      <email>szmeyes@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ShangHai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SuQing Yu</last_name>
      <phone>+86 137-0173-9566</phone>
      <email>sq-yu@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610047</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Zhang</last_name>
      <phone>+86 189-8060-2122</phone>
      <email>zhangmingscu@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Eye Hospital of WMU(Zhejiang eye hospital)</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325027</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>XiaoLing Liu</last_name>
      <phone>+86 137-5871-1161</phone>
      <email>drliuxiaolin@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>January 12, 2017</study_first_submitted>
  <study_first_submitted_qc>January 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2017</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neovascular Age-Related Macular Degeneration</keyword>
  <keyword>Anti-VEGF</keyword>
  <keyword>CNV</keyword>
  <keyword>TK001</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03021785
org study id: Tmab-TK001-AMD-02
nct id: NCT03021785
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
This is a multicenter, open-label study to evaluate the safety, pharmacokinetics,
      immunogenicity, and preliminary efficacy of multiple intravitreal injection TK001 in patients
      with AMD. It consists of core study (12 weeks) and extension study (40 weeks).
This is a multicenter, open-label study to evaluate the safety, pharmacokinetics,
      immunogenicity, and preliminary efficacy of multiple intravitreal injection TK001 in patients
      with AMD. It consists of core study (12 weeks) and extension study (40 weeks). In the core
      study, patients will receive their assigned dose in a 50-μL solution administered as an
      intravitreal injection every 4 weeks. In the extension study, they will be evaluated every 4
      weeks and administrated PRN (pro re nata) with their assigned dose. The safety,
      pharmacokinetics, immunogenicity, and preliminary efficacy of TK001 will be evaluated in the
      core study, and will also be assessed in the extension study except pharmacokinetics.
allocation: Non-Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Frequency of ocular and systemic AEs (adverse events) and SAEs (serious adverse events) which are related to TK001 in the first 12 weeks
time frame: 12 weeks
description: Core Study
measure: Frequency of ocular and systemic AEs (adverse events) and SAEs (serious adverse events) which are related to TK001 in the following 40 weeks
time frame: 40 weeks
description: Extension Study
measure: Area under the plasma concentration-time curve (AUC)
time frame: 12 weeks
description: Core Study
measure: Maximum plasma concentration (Cmax)
time frame: 12 weeks
description: Core Study
measure: Time to reach maximum concentration (Tmax)
time frame: 12 weeks
description: Core Study
measure: Elimination half-Life (T½)
time frame: 12 weeks
description: Core Study
measure: Change from baseline in the Best Corrected Visual Acuity at 12 weeks
time frame: 12 weeks
description: Core Study
measure: Change from baseline in the mean central retinal thickness at 12 weeks
time frame: 12 weeks
description: Core Study
measure: Change from baseline in the thickness of choroidal neovascularization at 12 weeks
time frame: 12 weeks
description: Core Study
measure: Change from baseline in the retinal thickness in the site of lesion which was the thickest at 12 weeks
time frame: 12 weeks
description: Core Study
measure: Change from baseline in macular volume at 12 weeks
time frame: 12 weeks
description: Core Study
measure: Change from baseline in the area of choroidal neovascularization at 12 weeks
time frame: 12 weeks
description: Core Study
measure: Change from baseline in the area of leakage at 12 weeks
time frame: 12 weeks
description: Core Study
measure: Change from baseline in the total lesion size at 12 weeks
time frame: 12 weeks
description: Core Study
measure: Percentage of Participants Positive for anti-TK001 antibody at 12 weeks
time frame: 12 weeks
description: Core Study
measure: Change from baseline in the Best Corrected Visual Acuity at 52 weeks
time frame: 40 weeks
description: Extension Study
measure: Change from baseline in the mean central retinal thickness at 52 weeks
time frame: 40 weeks
description: Extension Study
measure: Change from baseline in the thickness of choroidal neovascularization at 52 weeks
time frame: 40 weeks
description: Extension Study
measure: Change from baseline in the retinal thickness in the site of lesion which was the thickest at 52 weeks
time frame: 40 weeks
description: Extension Study
measure: Change from baseline in macular volume at 52 weeks
time frame: 40 weeks
description: Extension Study
measure: Change from baseline in the area of choroidal neovascularization at 52 weeks
time frame: 40 weeks
description: Extension Study
measure: Change from baseline in the area of leakage at 52 weeks
time frame: 40 weeks
description: Extension Study
measure: Change from baseline in the total lesion size at 52 weeks
time frame: 40 weeks
description: Extension Study
measure: Percentage of Participants Positive for anti-TK001 antibody at 52 weeks
time frame: 40 weeks
description: Extension Study
arm group label: 0.5mg
arm group type: Experimental
description: In the core study, patients will receive 0.5mg TK001 in a 50-μL solution administered as an intravitreal injection every 4 weeks. In the extension study, they will be evaluated every 4 weeks and administrated PRN (pro re nata) with their assigned dose.
arm group label: 1.0mg
arm group type: Experimental
description: In the core study, patients will receive 1.0mg TK001 in a 50-μL solution administered as an intravitreal injection every 4 weeks. In the extension study, they will be evaluated every 4 weeks and administrated PRN (pro re nata) with their assigned dose.
arm group label: 1.5mg
arm group type: Experimental
description: In the core study, patients will receive 1.5mg TK001 in a 50-μL solution administered as an intravitreal injection every 4 weeks. In the extension study, they will be evaluated every 4 weeks and administrated PRN (pro re nata) with their assigned dose.
intervention type: Biological
intervention name: TK001
description: TK001 will be administered intravitreal injection.
arm group label: 0.5mg
arm group label: 1.0mg
arm group label: 1.5mg
other name: anti-VEGF humanized monoclonal antibody injection
criteria: 
gender: All
minimum age: 45 Years
maximum age: 80 Years
healthy volunteers: No
last name: Ming Zhang
role: Principal Investigator
affiliation: West China Hospital
last name: Hongwei Miao
phone: +86(21)61160520
email: miaohongwei@sh-qingfeng.net
facility: 
status: Not yet recruiting
contact: 
facility: 
status: Not yet recruiting
contact: 
facility: 
status: Not yet recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Not yet recruiting
contact: 
country: China
responsible party type: Sponsor
mesh term: Macular Degeneration
mesh term: Wet Macular Degeneration
sharing ipd: Undecided